ClinicalTrials.gg
CompletedNCT00441103IMPROVEUpdated Jul 9, 2014Results posted

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

A Phase 3 interventional study of Rebif® New Formulation (IFN-beta-1a, RNF) and Placebo in Multiple Sclerosis, Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-07-09.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Merck KGaA, Darmstadt, Germany.

Enrollment
12th of 21
180 · median 200
Started
2006
with 3 others
Phase 3
8 of 40
none open now
Registered
8th of 40
by date

Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 12th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2006, is one of 8 in phase 3, and was the 8th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany as a file.
02

Study summary

General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes.

Objectives:

Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a [IFN-beta-1a], RNF), compared to placebo, in subjects with Relapsing Remitting Multiple Sclerosis and active disease by means of Magnetic Resonance Imaging (MRI) at the end of 16 weeks of treatment Secondary: To evaluate the efficacy of RNF by comparing the mean number of combined unique (CU) lesions per scan per subject between the initial 16 weeks of placebo treatment and 24 weeks of RNF treatment in the same subjects, originally randomized to placebo.

Primary Endpoints: The primary endpoint is the difference between the number of CU active MRI lesions at Week 16 in the RNF group (Group 1) versus the placebo group (Group 2).

Secondary Endpoints: The secondary endpoint is the difference in the mean number of CU active MRI lesions per scan per subject over the following treatment periods: Study Day 1 - Week 16 versus Weeks 17 - 40 for the subjects randomized to Group 2.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Subjects with relapsing remitting multiple sclerosis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 60 years of age
  • Female subjects must be neither pregnant nor breast-feeding and must lack , as defined by either: or surgically sterile or use an effective method of for the duration of the study
  • Have Relapsing Remitting Multiple Sclerosis (RRMS) according to the revised McDonald criteria 2005
  • Have brain and/or spinal MRI with findings typical of Multiple Sclerosis (MS)
  • Have disease duration for more than 12 months
  • Have disease activity characterized by at least one clinical event and one or more Gadolinium-enhancing MRI lesions within the 6 months prior to randomization
  • Have score of \<=5.5 on the Expanded Disability Status Scale (EDSS)
  • Be willing and able to comply with the protocol for the duration of the study
  • Have given written prior to any study-related procedure not part of the normal medical practice

Exclusion criteria

Exclusion Criteria:

  • Have any disease other than MS that could better explain his/her signs and symptoms
  • Have complete transverse myelitis or bilateral optic neuritis
  • Have received or have used anytime monoclonal antibodies, mitoxantrone, cytotoxic or therapy (excluding systemic and adrenocorticotrophic hormone [ACTH]), or total lymphoid irradiation
  • Have received within 3 months prior to baseline any approved disease-modifying therapy for MS, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, any drug, or experimental procedure
  • Have received within 30 days prior to baseline oral or systemic corticosteroids or ACTH
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Rebif® New Formulation (IFN-beta-1a, RNF)

    Drug: Rebif® New Formulation (IFN-beta-1a, RNF)

  • Placebo comparator
    Placebo/RNF

    Drug: Placebo · Drug: Rebif® New Formulation (IFN-beta-1a, RNF)

Interventions

  • DrugRebif® New Formulation (IFN-beta-1a, RNF)

    RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.

    Also known as: IFN-beta-1a

  • DrugPlacebo

    Matching placebo will be administered subcutaneously three times a week for 16 weeks.

  • DrugRebif® New Formulation (IFN-beta-1a, RNF)

    RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.

    Also known as: IFN-beta-1a

06

What researchers measure

Primary outcomes

  1. Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16

    CU active lesions were defined as a unique newly active or persistently active lesion on the protocol density/time constant 2 (PD/T2) scan or the gadolinium (Gd-) enhanced time constant 1 (T1) scan (with a method to avoid double counting).

    Time frame: 16 Weeks

  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. AEs were categorized based upon the treatment period during which they occurred, that is, double-blind period (up to Week 16) and rater-blind period (Week 17 up to Week 40).

    Time frame: Baseline up to Week 40

Secondary outcomes

  1. Mean Number of CU Lesions Per Scan Between the Initial 16 Weeks of Placebo Treatment and 24 Weeks of RNF Treatment in the Same Participants, Originally Randomized to Placebo.

    CU active lesions were defined as a unique newly active or persistently active lesion on the PD/T2 scan or the gadolinium enhanced T1 scan (with a method to avoid double counting). Only "Placebo Followed by RNF" arm was evaluable for this outcome measure.

    Time frame: Day 1 up to Week 16 and Week 17 up to Week 40

  2. Number of CU Active MRI Lesions

    CU active lesions were defined as a unique newly active or persistently active lesion on the PD/T2 scan or the gadolinium enhanced T1 scan (with a method to avoid double counting).

    Time frame: Up to Week 40

07

Results

Posted Jul 5, 2010

Participant flow

Date of first participant first visit: 15 Dec 2006. Date of last participant last visit: 28 Nov 2008. Twenty five trial centers enrolled participants in the following countries: Bulgaria (7), Canada(2), Estonia (2), Germany (1), Italy(2), Lithuania (1), Romania (1), Russian Federation (4), Serbia (2), and Spain (3).

Participant flow — Overall Study
MilestoneRebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNF
Started12060
Completed10956
Not completed114
Withdrew: Adverse event21
Withdrew: Death10
Withdrew: Disease progression20
Withdrew: Lost to follow-up10
Withdrew: Protocol violation10
Withdrew: Participant unable to use rebiject ii10
Withdrew: Participant refused mri10
Withdrew: Inclusion criteria absent10
Withdrew: Non-compliant01
Withdrew: Participant decided to withdraw10
Withdrew: Participant's reason01
Withdrew: Participant decided to stop01

Outcome measures

PrimaryNumber of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16

CU active lesions were defined as a unique newly active or persistently active lesion on the protocol density/time constant 2 (PD/T2) scan or the gadolinium (Gd-) enhanced time constant 1 (T1) scan (with a method to avoid double counting).

Time frame:
16 Weeks
Reported as:
Mean · lesions
Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16
lesionsRebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNF
Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 160.9 ± 1.43.0 ± 4.1
Statistical analysis
  • Rebif® New Formulation (IFN-beta-1a, RNF) vs Placebo/RNF · ANOVA · p = <0.001 (Non-parametric analysis of variance (ANOVA) with effects for treatment and the absence/presence of Gd-enhancing lesions at baseline as factors)
SecondaryMean Number of CU Lesions Per Scan Between the Initial 16 Weeks of Placebo Treatment and 24 Weeks of RNF Treatment in the Same Participants, Originally Randomized to Placebo.

CU active lesions were defined as a unique newly active or persistently active lesion on the PD/T2 scan or the gadolinium enhanced T1 scan (with a method to avoid double counting). Only "Placebo Followed by RNF" arm was evaluable for this outcome measure.

Time frame:
Day 1 up to Week 16 and Week 17 up to Week 40
Reported as:
Mean · lesions
Mean Number of CU Lesions Per Scan Between the Initial 16 Weeks of Placebo Treatment and 24 Weeks of RNF Treatment in the Same Participants, Originally Randomized to Placebo.
lesionsPlacebo/RNF
Day 1 up to Week 162.31 ± 2.63
Week 17 up to Week 400.65 ± 0.95
Statistical analysis
  • Placebo/RNF · Wilcoxon signed-rank test · p = <0.001 · Mean difference (final values): -1.67
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. AEs were categorized based upon the treatment period during which they occurred, that is, double-blind period (up to Week 16) and rater-blind period (Week 17 up to Week 40).

Time frame:
Baseline up to Week 40
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsRebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNF
AEs during double-blind period (n = 120, 60)10039
AEs during rater-blind period (n = 112, 57)7243
SAEs during overall period (n = 120, 60)43
SecondaryNumber of CU Active MRI Lesions

CU active lesions were defined as a unique newly active or persistently active lesion on the PD/T2 scan or the gadolinium enhanced T1 scan (with a method to avoid double counting).

Time frame:
Up to Week 40
Reported as:
Mean · lesions
Number of CU Active MRI Lesions
lesionsRebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNF
Number of CU Active MRI Lesions0.62 ± 1.291.27 ± 1.33

Adverse events

Collected over Baseline up to Week 40. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rebif® New Formulation (IFN-beta-1a, RNF)—4/120 (3.3%)100/120 (83.3%)
Placebo/RNF—3/60 (5%)39/60 (65%)
Most frequent serious events
Most frequent serious events
EventRebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNF
Carpal tunnel syndromeNervous system disorders0/1201/60
FallInjury, poisoning and procedural complications0/1201/60
Joint dislocationInjury, poisoning and procedural complications0/1201/60
Back painMusculoskeletal and connective tissue disorders0/1201/60
TonsillitisInfections and infestations1/1200/60
Pulmonary tuberculosisInfections and infestations1/1200/60
Pyelonephritis acuteInfections and infestations1/1200/60
Road traffic accidentInjury, poisoning and procedural complications1/1200/60
Most frequent other events
Showing 10 of 18
Most frequent other events
EventRebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNF
Influenza like illnessGeneral disorders60/12010/60
Injection site erythemaGeneral disorders39/1204/60
HeadacheNervous system disorders37/12010/60
Injection site painGeneral disorders12/1201/60
PyrexiaGeneral disorders9/1203/60
AstheniaGeneral disorders8/1203/60
ChillsGeneral disorders8/1201/60
DizzinessNervous system disorders3/1204/60
Upper respiratory tract infectionInfections and infestations4/1204/60
FatigueGeneral disorders7/1200/60

Baseline characteristics

Intent to treat (ITT) population included all randomized participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)Rebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNFTotal
<=18 years000
Between 18 and 65 years12060180
>=65 years000
Age, Continuous
Age, Continuous(years)Rebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNFTotal
Mean34.0 ± 7.835.2 ± 10.534.4 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Rebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNFTotal
Female8842130
Male321850
Region of Enrollment
Region of Enrollment(participants)Rebif® New Formulation (IFN-beta-1a, RNF)Placebo/RNFTotal
Bulgaria401252
Canada336
Estonia8513
Germany101
Italy7411
Lithuania538
Romania11819
Russian Federation201232
Serbia20929
Spain549
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • De Stefano N, Curtin F, Stubinski B, Blevins G, Drulovic J, Issard D, Shotekov P, Gasperini C; IMPROVE Study Investigators. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. Mult Scler. 2010 Jul;16(7):888-92. doi: 10.1177/1352458510362442. Epub 2010 Mar 3. PubMed 20200197 ↗
  • De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. J Neurol Sci. 2012 Jan 15;312(1-2):97-101. doi: 10.1016/j.jns.2011.08.013. Epub 2011 Aug 31. PubMed 21880336 ↗
  • Giorgio A, Battaglini M, Gentile G, Stromillo ML, Gasperini C, Visconti A, Paolillo A, De Stefano N. Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis. Front Neurol. 2020 Nov 20;11:585296. doi: 10.3389/fneur.2020.585296. eCollection 2020. PubMed 33329329 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Nov 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2007
First posted
Feb 28, 2007
Start
Dec 2006
Primary completionActual
Nov 2008
CompletionActual
Feb 2009
Results first posted
Jul 5, 2010
Last update
Jul 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00441103
Responsible party
Sponsor
First posted
Feb 28, 2007
Start date
Dec 2006
Primary completion
Nov 2008
Completion
Feb 2009
Results posted
Jul 5, 2010
Last update
Jul 9, 2014

Study contacts

Bettina Stubinski, MD
study director · Merck Serono SA - Geneva, an affiliate of Merck KGaA Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion